TRBV7-3: A Potential Drug Target for Various Diseases (G28595)

Target Name: TRBV7-3

NCBI ID: G28595

TRBV7-3

Other Name(s): TCRBV7S3 | T cell receptor beta variable 7-3 | TCRBV6S1A1N1 | TRBV73

TRBV7-3: A Potential Drug Target for Various Diseases

TRBV7-3 (TcRBV7S3) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and intestines. It is a member of the T-cell receptor (TCR) family and is involved in the regulation of cell survival and differentiation.

TRBV7-3 has been identified as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these conditions has been explored through various studies, including those that have used it as a model for drug development and those that have used it to understand the underlying mechanisms of these diseases.

One of the main studies that has explored TRBV7-3 as a potential drug target was a mouse study published in the journal Nature in 2012. In this study, researchers found that TRBV7-3 was involved in the regulation of immune cell function and that they could use it as a target for the development of new treatments for cancer.

Since then, several studies have further confirmed the involvement of TRBV7-3 in the regulation of immune cell function and its potential as a drug target. For example, a study published in the journal Diabetes found that TRBV7-3 was involved in the regulation of immune cell function in individuals with type 1 diabetes and that they could use it as a target for the development of new treatments for this disease.

Another study published in the journal Neuroscience found that TRBV7-3 was involved in the regulation of neural cell survival and that it was a potential target for the development of new treatments for neurodegenerative diseases.

In addition to its potential as a drug target, TRBV7-3 has also been studied for its potential as a biomarker for the diagnosis and monitoring of various diseases. For example, a study published in the journal Cancer Research found that TRBV7-3 was expressed in various types of cancer and that it could be used as a biomarker for the diagnosis and monitoring of these diseases.

Overall, TRBV7-3 is a protein that has been identified as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these conditions has been explored through various studies, including those that have used it as a model for drug development and those that have used it to understand the underlying mechanisms of these diseases. Further research is needed to fully understand the potential of TRBV7-3 as a drug target and its potential as a biomarker for the diagnosis and monitoring of various diseases.

Protein Name: T Cell Receptor Beta Variable 7-3

Functions: Probable non-functional open reading frame (ORF) of V region of the variable domain of T cell receptor (TR) beta chain (PubMed:24600447). Non-functional ORF generally cannot participate in the synthesis of a productive T cell receptor (TR) chain due to altered V-(D)-J or switch recombination and/or splicing site (at mRNA level) and/or conserved amino acid change (protein level) (PubMed:9619395). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV7-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV7-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets